GLUL and metastatic neoplasm: In the bone metastatic tumor fraction, we observed an increased average expression of glutamine transporter SLC1A5 (ASCT2), glutamine utilizing enzymes GLS, glutamine-fructose-6-phosphate transaminase (GFPT1), phosphoribosyl pyrophosphate amidotransferase (PPAT), glutamine synthetase (GLUL), and glycolytic enzyme hexokinase (HK2) relative to the benign or distal bone marrow (BM) fraction.